Time to reconsider the role of sentinel lymph node biopsy in melanoma
被引:23
|
作者:
Bigby, Michael
论文数: 0引用数: 0
h-index: 0
机构:
Harvard Med Sch, Dept Dermatol, Boston, MA 02215 USA
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USAHarvard Med Sch, Dept Dermatol, Boston, MA 02215 USA
Bigby, Michael
[1
,2
]
Zagarella, Samuel
论文数: 0引用数: 0
h-index: 0
机构:
Univ Sydney, Dept Dermatol, Sch Med, Sydney, NSW, AustraliaHarvard Med Sch, Dept Dermatol, Boston, MA 02215 USA
Zagarella, Samuel
[3
]
Sladden, Michael
论文数: 0引用数: 0
h-index: 0
机构:
Univ Tasmania, Dept Med, Sch Med, Launceston, Tas, AustraliaHarvard Med Sch, Dept Dermatol, Boston, MA 02215 USA
Sladden, Michael
[4
]
Popescu, Catalin M.
论文数: 0引用数: 0
h-index: 0
机构:
Carol Davila Univ Med & Pharm, Bucharest, RomaniaHarvard Med Sch, Dept Dermatol, Boston, MA 02215 USA
Popescu, Catalin M.
[5
]
机构:
[1] Harvard Med Sch, Dept Dermatol, Boston, MA 02215 USA
[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[3] Univ Sydney, Dept Dermatol, Sch Med, Sydney, NSW, Australia
[4] Univ Tasmania, Dept Med, Sch Med, Launceston, Tas, Australia
[5] Carol Davila Univ Med & Pharm, Bucharest, Romania
The Multicenter Selective Lymphadenectomy Trials indicate that there are no overall or melanoma-specific survival advantages to performing sentinel lymph node biopsy (SLNB) followed by immediate completion lymph node dissection compared with wide excision and observation for patients with positive sentinel nodes. These results make SLNB solely a staging procedure. The role of SLNB in the management of patients with melanoma deserves reappraisal. The potential marginal benefit of SLNB beyond the clinical and pathologic features of the melanoma has not been well studied. The use of sentinel lymph node status alone to accept and stratify patients into trials or to receive adjuvant treatment is not rational.